News

In part 4 of this 5-part HCPLive RX Review, experts discuss how the availability of new therapeutic options are changing the treatment paradigm in C3G.

In part 3 of this 5-part HCPLive RX Review, experts discuss VALIANT data supporting pegcetacoplan’s approval and how they compare to iptacopan.

In part 2 of this 5-part HCPLive RX Review, experts discuss how to utilize the newly FDA-approved therapies for treating C3G and what questions remain.

In part 1 of this 5-part HCPLive RX Review, experts discuss the current therapeutic landscape for C3G following 2 notable FDA approvals.

In this large study, oral berotralstat resulted in early and sustained reductions in HAE attack rates, offering a promising long-term prophylaxis option.

Recent phase 1/2 trial data indicate the safety and efficacy of the surgical, subretinal injection in monitoring cellular homeostasis.

Hosts offer perspective on the topline results from SURPASS-CVOT and what the cardiovascular data on tirzepatide means for care.

The PAISLEY CLE trial findings highlight deucravacitinib’s efficacy among patients with cutaneous lupus, including those with concurrent SLE.

This July psychiatry month in review features FDA news, depression trials, links between healthy habits and mental health, and SoCal Psych 2025 highlights.

July 2025 saw a number of updates in COPD management and new research on RSV and COVID.

Discover the evolving landscape of hypertriglyceridemia treatment, focusing on innovative therapies and improved diagnostic strategies for FCS and MCS.

This clinical episode of Skin of Color Savvy highlights the work of the International Alliance for Global Health Dermatology (GLODERM) and a new collaboration between GLODERM and SOCS.

In a study of children with food allergy and atopic dermatitis, longer dupilumab use was associated with significantly lower food-specific IgE levels.

Recent FDA approvals of pegcetacoplan and iptacopan revolutionize C3 glomerulopathy treatment, offering hope and targeted options for patients.

C3G treatment options expand with FDA approvals of pegcetacoplan and iptacopan, offering new hope for patient care.

This segment of Hebert’s DERM 2025 interview highlights additional conclusions from her team’s data on roflumilast in atopic dermatitis among infants and toddlers.

A 4.5 mm cut-off using the Skin Prick Automated Test showed comparable accuracy to the standard skin prick test in detecting birch pollen and house dust mite allergies.

Check out expert perspectives and new research on hepatitis C, cirrhosis, and more in this July 2025 recap.

The pooled sham cohorts of the OAKS and DERBY trials have revealed a series of indicators for faster geographic atrophy lesion growth.

Investigators believe this connection could be used to prognosticate and prevent future cases of diabetic retinopathy.

The combination therapy of aflibercept and micropulsed yellow laser treatment results in good anatomical responses and substantially fewer intravitreal injections.

The mitochondria-targeting medication preserves photoreceptor health regardless of baseline photoreceptor outer segment thinning burden.

Interim data from the ongoing TEASE-3 trial have indicated preservation of best-corrected visual acuity.

Compared to sham treatment, the PER-001 implant is safe, efficacious, and effective in reducing macular ischemia, vascular leakage, and microaneurysms.

Based on an open-label extension of the OAKS and DERBY trials, pegcetacoplan has highlighted the superior effectiveness of early versus delayed GA treatment.

Insights from Lungcast Interviews with Experts Leading the Charge in Detection and Therapy

Results from the DAVIO 2 trial have shown the equivalence of a single dose of EYP-1901 to aflibercept Q8W in visual acuity over 6 months.

In a DERM 2025 conference interview, Hebert highlights takeaways from her team’s findings on roflumilast cream in patients aged 3 months to 2 years with atopic dermatitis.